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Introduction
Familial Mediterranean Fever (FMF) is a genetic disorder
characterized by recurrent attacks of fever and pain,
which is most common in those of Sephardic Jewish,
Armenian, Turkish or Arabic descent. Although colchi-
cine is the mainstay of treatment for FMF, an estimated
5 to 15% of patients have an incomplete response to
colchicine (e.g. colchicine-resistance FMF [cr-FMF]).[1,2]
Objectives
To determine the impact of cr-FMF on patients’ or
caregivers’ lives, to describe patient’s journey from first
onset of symptoms to present, and to identify areas for
improvement in cr-FMF patient care.
Patients and methods
Patients with cr-FMF or their caregivers (paediatric
patients) (N=16) were recruited through rare disease
experts and patient support groups. Patients completed
a 20 page pre-interview questionnaire and an in-depth
90 minute interview. Complete data (n=14) were quanti-
fied with topics focused on symptoms, diagnosis process,
treatment experience, treatment needs and impact on
wellbeing.
Results
The majority of patients were adults (n=14) with a family
history of FMF (n=14). The disease generally starts in
childhood, with 65% of patients experiencing symptoms
before 10 years. Attacks occurred with variable fre-
quency, ranged from weekly to every 3-4 months, lasting
between 12-72 hours. Reported triggers included physical
or emotional stress, or menstruation or occured sponta-
neously. Commonly reported symptoms were stomach,
fever, joint pain, difficulty breathing and chest and
back pain. Diagnosis delays were also variable (4 months-
44 yrs), with half of patients experiencing delays of ~5
years. Flares were extremely debilitating and patients
were often bedridden, leading to missed work and school.
Entire families were impacted, especially caregivers.
Patients/caregivers were often dependant on family for
support and financial assistance. Most patients continue
to be treated with colchicine despite only partial response
and distressing side-effects. They expressed the need for
treatments that provided not only rapid relief during
flares, but also prevented or reduced attacks.
Conclusion
Patients with cr-FMF reported a significant impact of
the disease on physical, social, emotional, and practical/
financial aspects of their lives. In their journey with
cr-FMF, they commonly experienced diagnostic delays
and misdiagnoses. Therapeutic options with improved
efficacy and fewer side-effects are needed for the treat-
ment of cr-FMF.
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